Open AccessEffectiveness of high‐dose transvaginal progesterone supplementation for women who are undergoing a frozen‐thawed embryo transfer
Author(s) -
Enatsu Yihsien,
Enatsu Noritoshi,
Kishi Kanako,
Iwasaki Toshiro,
Matsumoto Yukiko,
Kokeguchi Shoji,
Shiotani Masahide
Publication year - 2018
Publication title -
reproductive medicine and biology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.005
H-Index - 22
eISSN - 1447-0578
pISSN - 1445-5781
DOI - 10.1002/rmb2.12096
Subject(s) - luteal phase , embryo transfer , medicine , pregnancy , pregnancy rate , logistic regression , live birth , gynecology , andrology , obstetrics , endocrinology , biology , hormone , genetics
Purpose To evaluate the effectiveness of high‐dose progesterone supplementation for women who are undergoing a frozen‐thawed embryo transfer ( FET ). Methods Among the 2010 FET cycles that were included in the present study, 1188 were 1200 mg/d of vaginal progesterone, while 822 were 900 mg/d. The dose of progesterone that was used was decided by the treatment period and additional progesterone supplementation was used when the serum progesterone levels were <9 ng/ mL on luteal day 5. Results The clinical pregnancy rate was higher in the 1200 mg group than in the 900 mg group. The mean serum progesterone level on luteal day 5 in the 1200 mg and 900 mg groups was 12.6 ng/ mL and 13.4 ng/ mL , respectively. The rate of additional progesterone supplementation was higher in the 1200 mg group. A logistic regression analysis identified a younger age (≤37 years) and the use of 1200 mg progesterone as independent predictive factors for the clinical pregnancy outcome. The analysis of the infant outcomes revealed no significant difference in the distribution of birth ages and weights. Conclusion High‐dose transvaginal progesterone of 1200 mg/d as luteal support contributed to good pregnancy outcomes.